Live Breaking News & Updates on Tarsus Pharmaceuticals Stock Down

Stay updated with breaking news from Tarsus pharmaceuticals stock down. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $49.88 Consensus Price Target from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price […] ....

United States , Bryan Wahl , Bobakr Azamian , Artisan Partners Limited Partnership , Hedge Funds Weigh In On Tarsus Pharmaceuticals , Securities Exchange Commission , Tarsus Pharmaceuticals Stock Down , Jennison Associates , News Ratings For Tarsus Pharmaceuticals Daily , Jefferies Financial Group , Pricet Rowe Associates Inc , Goldman Sachs Group , Healthcare Of Ontario Pension Plan Trust Fund , Deerfield Management Companylp Series , Tarsus Pharmaceuticals , Analyst Recommendations For Tarsus Pharmaceuticals , Insider Activity At Tarsus Pharmaceuticals , Tarsus Pharmaceuticals Inc , Get Free Report , Financial Group , Pharmaceuticals Stock Down , Exchange Commission , General Counsel Bryan Wahl , Ontario Pension Plan Trust Fund , Partners Limited Partnership , Pricet Rowe Associates ,

Tarsus Pharmaceuticals (NASDAQ:TARS) PT Raised to $61.00

Tarsus Pharmaceuticals (NASDAQ:TARS) PT Raised to $61.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Zurcher Kantonalbank Zurich Cantonalbank , Seshadri Neervannan , Bryan Wahl , Hedge Funds Weigh In On Tarsus Pharmaceuticals , Analyst Recommendations For Tarsus Pharmaceuticals , Tarsus Pharmaceuticals Inc , Tarsus Pharmaceuticals Stock Down , News Ratings For Tarsus Pharmaceuticals Daily , Raymond James Associates , Ieq Capital , China Universal Asset Management Co , Goldman Sachs Group , Tower Research Capital , Jefferies Financial Group , Tarsus Pharmaceuticals , Get Free Report , Financial Group , Pharmaceuticals Stock Down , General Counsel Bryan Wahl , Universal Asset Management , Research Capital , Kantonalbank Zurich Cantonalbank , Tarsus Pharmaceuticals Daily ,

Vivo Capital LLC Has $36.13 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Vivo Capital LLC Has $36.13 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United States , Bryan Wahl , Aziz Mottiwala , Zurcher Kantonalbank Zurich Cantonalbank , Tarsus Pharmaceuticals Stock Down , Mirae Asset Global Investments Co , Goldman Sachs Group , Tarsus Pharmaceuticals Inc , News Ratings For Tarsus Pharmaceuticals Daily , Securities Exchange Commission , China Universal Asset Management Co , Jefferies Financial Group , Vivo Capital , Quarter For Tarsus Pharmaceuticals , Raymond James Associates , Ieq Capital , Tarsus Pharmaceuticals , Free Report , Universal Asset Management , Kantonalbank Zurich Cantonalbank , Mirae Asset Global Investments , Pharmaceuticals Stock Down , Get Free Report , General Counsel Bryan Wahl , Exchange Commission , Financial Group ,

Guggenheim Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $49.00

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its price objective hoisted by equities researchers at Guggenheim from $46.00 to $49.00 in a report released on Monday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 198.23% from the stock’s previous close. Several […] ....

United States , William Blair , Bobakr Azamian , Blackrock Inc , Securities Exchange Commission , Tarsus Pharmaceuticals , Tarsus Pharmaceuticals Company Profile , Tarsus Pharmaceuticals Inc , News Ratings For Tarsus Pharmaceuticals Daily , Vanguard Group Inc , Tarsus Pharmaceuticals Stock Down , Institutional Investors Weigh In On Tarsus Pharmaceuticals , Jefferies Financial Group Inc , Get Free Report , Marketbeat Ratings , Pharmaceuticals Stock Down , Exchange Commission , Financial Group , Exoduspoint Capital Management , Tarsus Pharmaceuticals Daily , Nasdaq Tars , Boost Price Target ,

Tarsus Pharmaceuticals (NASDAQ:TARS) Earns "Buy" Rating from Guggenheim

Guggenheim restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a report issued on Monday morning, Benzinga reports. They currently have a $46.00 price objective on the stock. TARS has been the topic of several other reports. William Blair assumed coverage on Tarsus Pharmaceuticals in a research report on Tuesday, […] ....

United States , Aziz Mottiwala , William Blair , Bobakr Azamian , Tarsus Pharmaceuticals , Wells Fargo Company , Tarsus Pharmaceuticals Stock Down , Goldman Sachs Group Inc , Tarsus Pharmaceuticals Company Profile , News Ratings For Tarsus Pharmaceuticals Daily , Tarsus Pharmaceuticals Inc , Royal Bank , Institutional Investors Weigh In On Tarsus Pharmaceuticals , Securities Exchange Commission , Free Report , Pharmaceuticals Stock Down , Get Free Report , Exchange Commission , Employees Retirement System , Sachs Group , Tarsus Pharmaceuticals Daily , Nasdaq Tars , Reiterated Rating ,